Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

LATS2 is De-methylated and Overexpressed in Nasopharyngeal Carcinoma and Predicts Poor Prognosis

Authors: Yan Zhang, Chun-Fang Hu, Jing Chen, Li-Xu Yan, Yi-Xin Zeng, Jian-Yong Shao

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

LATS2, which encodes a novel serine/threonine kinase, is known to be important in centrosome duplication and in the maintenance of genomic stability. Recently, a potential role for LATS2 in cancer has been reported. In breast cancer and acute lymphoblastic leukemia (ALL), LATS2 mRNA is downregulated and has been suggested to be a tumor suppressor. However, the role of LATS2 in nasopharyngeal carcinoma has not been investigated. In this study, we aimed to investigate the expression pattern of LATS2 and its clinicopathological involvement in nasopharyngeal carcinoma to understand its effect on cell survival.

Methods

Using quantitative real time PCR and immunoblotting, the expression of LATS2 was detected in nasopharyngeal carcinoma cell lines and in the immortalized nasopharyngeal epithelial cell line NP69. Using immunohistochemistry, we analyzed LATS2 protein expression in 220 nasopharyngeal carcinoma cases. The association of LATS2 protein expression with the clinicopathological characteristics and the prognosis of nasopharyngeal carcinoma were subsequently assessed. Using methylation specific PCR, we detected the methylation status of the LATS2 promoter. RNA interference was performed by transfecting siRNA to specifically knock down LATS2 expression in 5-8F and CNE2.

Results

LATS2 protein was detected in 178 of 220 (80.91%) cases of nasopharyngeal carcinoma. LATS2 overexpression was a significant, independent prognosis predictor (P = 0.037) in nasopharyngeal carcinoma patients. Methylation specific PCR revealed that 36.7% (11/30) of nasopharyngeal carcinoma tissues and all of the chronic nasopharyngeal inflammation samples were methylated. Functional studies showed that the suppression of LATS2 expression in nasopharyngeal carcinoma (5-8F and CNE2) cell lines by using specific small interfering (siRNA) resulted in the inhibition of growth, induction of apoptosis and S-phase cell cycle increase. Overexpression of LATS2 in NP69 stimulated cell proliferation.

Conclusions

Our results indicate that LATS2 might play a role in the tumorigenesis of nasopharyngeal carcinoma by promoting the growth of nasopharyngeal carcinoma cells. Transfection with specific siRNA might be feasible for the inhibition of growth, induction of apoptosis and S phase increase in nasopharyngeal carcinoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chang ET, Adami HO: The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006, 15: 1765-77. 10.1158/1055-9965.EPI-06-0353.CrossRefPubMed Chang ET, Adami HO: The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006, 15: 1765-77. 10.1158/1055-9965.EPI-06-0353.CrossRefPubMed
2.
go back to reference Klibi J, Niki T, Riedel A, et al: Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood. 2009, 113: 1957-66. 10.1182/blood-2008-02-142596.CrossRefPubMed Klibi J, Niki T, Riedel A, et al: Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood. 2009, 113: 1957-66. 10.1182/blood-2008-02-142596.CrossRefPubMed
3.
go back to reference Airoldi M, Gabriele AM, Garzaro M, et al: Induction chemotherapy with cysplatin and epirubicin followed by radiotherapy and concurrent cysplatin in locally advanced nasopharyngeal carcinoma observed in a non-endemic population. Radiother Oncol. 2009 Airoldi M, Gabriele AM, Garzaro M, et al: Induction chemotherapy with cysplatin and epirubicin followed by radiotherapy and concurrent cysplatin in locally advanced nasopharyngeal carcinoma observed in a non-endemic population. Radiother Oncol. 2009
4.
go back to reference Chen Y, Liu MZ, Liang SB, et al: Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys. 2008, 71: 1356-64.CrossRefPubMed Chen Y, Liu MZ, Liang SB, et al: Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys. 2008, 71: 1356-64.CrossRefPubMed
5.
go back to reference Farias TP, Dias FL, Lima RA, et al: Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2003, 129: 794-9. 10.1001/archotol.129.7.794.CrossRefPubMed Farias TP, Dias FL, Lima RA, et al: Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2003, 129: 794-9. 10.1001/archotol.129.7.794.CrossRefPubMed
6.
go back to reference Heng DM, Wee J, Fong KW, et al: Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer. 1999, 86: 1912-20. 10.1002/(SICI)1097-0142(19991115)86:10<1912::AID-CNCR6>3.0.CO;2-S.CrossRefPubMed Heng DM, Wee J, Fong KW, et al: Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer. 1999, 86: 1912-20. 10.1002/(SICI)1097-0142(19991115)86:10<1912::AID-CNCR6>3.0.CO;2-S.CrossRefPubMed
7.
go back to reference Hong MH, Mai HQ, Min HQ, Ma J, Zhang EP, Cui NJ: A comparison of the Chinese 1992 and fifth-edition International Union Against Cancer staging systems for staging nasopharyngeal carcinoma. Cancer. 2000, 89: 242-7. 10.1002/1097-0142(20000715)89:2<242::AID-CNCR6>3.0.CO;2-Z.CrossRefPubMed Hong MH, Mai HQ, Min HQ, Ma J, Zhang EP, Cui NJ: A comparison of the Chinese 1992 and fifth-edition International Union Against Cancer staging systems for staging nasopharyngeal carcinoma. Cancer. 2000, 89: 242-7. 10.1002/1097-0142(20000715)89:2<242::AID-CNCR6>3.0.CO;2-Z.CrossRefPubMed
8.
go back to reference Ayan I, Kaytan E, Ayan N: Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol. 2003, 4: 13-21. 10.1016/S1470-2045(03)00956-2.CrossRefPubMed Ayan I, Kaytan E, Ayan N: Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol. 2003, 4: 13-21. 10.1016/S1470-2045(03)00956-2.CrossRefPubMed
9.
go back to reference Cao Y, Miao XP, Huang MY, et al: Polymorphisms of XRCC1 genes and risk of nasopharyngeal carcinoma in the Cantonese population. BMC Cancer. 2006, 6: 167-10.1186/1471-2407-6-167.CrossRefPubMedPubMedCentral Cao Y, Miao XP, Huang MY, et al: Polymorphisms of XRCC1 genes and risk of nasopharyngeal carcinoma in the Cantonese population. BMC Cancer. 2006, 6: 167-10.1186/1471-2407-6-167.CrossRefPubMedPubMedCentral
10.
go back to reference Shao JY, Zhang Y, Li YH, et al: Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. Anticancer Res. 2004, 24: 4059-66.PubMed Shao JY, Zhang Y, Li YH, et al: Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. Anticancer Res. 2004, 24: 4059-66.PubMed
11.
go back to reference Lo KW, To KF, Huang DP: Focus on nasopharyngeal carcinoma. Cancer Cell. 2004, 5: 423-8. 10.1016/S1535-6108(04)00119-9.CrossRefPubMed Lo KW, To KF, Huang DP: Focus on nasopharyngeal carcinoma. Cancer Cell. 2004, 5: 423-8. 10.1016/S1535-6108(04)00119-9.CrossRefPubMed
12.
go back to reference Guo X, Johnson RC, Deng H, et al: Evaluation of nonviral risk factors for nasopharyngeal carcinoma in a high-risk population of Southern China. Int J Cancer. 2009, 124: 2942-7. 10.1002/ijc.24293.CrossRefPubMedPubMedCentral Guo X, Johnson RC, Deng H, et al: Evaluation of nonviral risk factors for nasopharyngeal carcinoma in a high-risk population of Southern China. Int J Cancer. 2009, 124: 2942-7. 10.1002/ijc.24293.CrossRefPubMedPubMedCentral
13.
go back to reference Lu L, Li Y, Kim SM, et al: Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA. 107: 1437-42. 10.1073/pnas.0911427107. Lu L, Li Y, Kim SM, et al: Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA. 107: 1437-42. 10.1073/pnas.0911427107.
14.
15.
go back to reference Matsui Y, Nakano N, Shao D, et al: Lats2 is a negative regulator of myocyte size in the heart. Circ Res. 2008, 103: 1309-18. 10.1161/CIRCRESAHA.108.180042.CrossRefPubMedPubMedCentral Matsui Y, Nakano N, Shao D, et al: Lats2 is a negative regulator of myocyte size in the heart. Circ Res. 2008, 103: 1309-18. 10.1161/CIRCRESAHA.108.180042.CrossRefPubMedPubMedCentral
16.
go back to reference Kamikubo Y, Takaori-Kondo A, Uchiyama T, Hori T: Inhibition of cell growth by conditional expression of kpm, a human homologue of Drosophila warts/lats tumor suppressor. J Biol Chem. 2003, 278: 17609-14. 10.1074/jbc.M211974200.CrossRefPubMed Kamikubo Y, Takaori-Kondo A, Uchiyama T, Hori T: Inhibition of cell growth by conditional expression of kpm, a human homologue of Drosophila warts/lats tumor suppressor. J Biol Chem. 2003, 278: 17609-14. 10.1074/jbc.M211974200.CrossRefPubMed
17.
go back to reference Li Y, Pei J, Xia H, Ke H, Wang H, Tao W: Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene. 2003, 22: 4398-405. 10.1038/sj.onc.1206603.CrossRefPubMed Li Y, Pei J, Xia H, Ke H, Wang H, Tao W: Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene. 2003, 22: 4398-405. 10.1038/sj.onc.1206603.CrossRefPubMed
18.
go back to reference Ke H, Pei J, Ni Z, et al: Putative tumor suppressor Lats2 induces apoptosis through downregulation of Bcl-2 and Bcl-x(L). Exp Cell Res. 2004, 298: 329-38. 10.1016/j.yexcr.2004.04.031.CrossRefPubMed Ke H, Pei J, Ni Z, et al: Putative tumor suppressor Lats2 induces apoptosis through downregulation of Bcl-2 and Bcl-x(L). Exp Cell Res. 2004, 298: 329-38. 10.1016/j.yexcr.2004.04.031.CrossRefPubMed
19.
go back to reference Aylon Y, Michael D, Shmueli A, Yabuta N, Nojima H, Oren M: A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev. 2006, 20: 2687-700. 10.1101/gad.1447006.CrossRefPubMedPubMedCentral Aylon Y, Michael D, Shmueli A, Yabuta N, Nojima H, Oren M: A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev. 2006, 20: 2687-700. 10.1101/gad.1447006.CrossRefPubMedPubMedCentral
20.
go back to reference McPherson JP, Tamblyn L, Elia A, et al: Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity. EMBO J. 2004, 23: 3677-88. 10.1038/sj.emboj.7600371.CrossRefPubMedPubMedCentral McPherson JP, Tamblyn L, Elia A, et al: Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity. EMBO J. 2004, 23: 3677-88. 10.1038/sj.emboj.7600371.CrossRefPubMedPubMedCentral
21.
go back to reference Yabuta N, Okada N, Ito A, et al: Lats2 is an essential mitotic regulator required for the coordination of cell division. J Biol Chem. 2007, 282: 19259-71. 10.1074/jbc.M608562200.CrossRefPubMed Yabuta N, Okada N, Ito A, et al: Lats2 is an essential mitotic regulator required for the coordination of cell division. J Biol Chem. 2007, 282: 19259-71. 10.1074/jbc.M608562200.CrossRefPubMed
22.
go back to reference Min H, Hong M, Ma J, et al: A new staging system for nasopharyngeal carcinoma in China. Int J Radiat Oncol Biol Phys. 1994, 30: 1037-42.CrossRefPubMed Min H, Hong M, Ma J, et al: A new staging system for nasopharyngeal carcinoma in China. Int J Radiat Oncol Biol Phys. 1994, 30: 1037-42.CrossRefPubMed
23.
go back to reference Li YH, Hu CF, Shao Q, et al: Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J Transl Med. 2008, 6: 1-10.1186/1479-5876-6-1.CrossRefPubMedPubMedCentral Li YH, Hu CF, Shao Q, et al: Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J Transl Med. 2008, 6: 1-10.1186/1479-5876-6-1.CrossRefPubMedPubMedCentral
24.
go back to reference Du ZM, Hu CF, Shao Q, et al: Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. Int J Cancer. 2009 Du ZM, Hu CF, Shao Q, et al: Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. Int J Cancer. 2009
25.
go back to reference Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000, 25: 315-9. 10.1038/77083.CrossRefPubMed Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000, 25: 315-9. 10.1038/77083.CrossRefPubMed
26.
go back to reference Takahashi Y, Miyoshi Y, Takahata C, et al: Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res. 2005, 11: 1380-5. 10.1158/1078-0432.CCR-04-1773.CrossRefPubMed Takahashi Y, Miyoshi Y, Takahata C, et al: Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res. 2005, 11: 1380-5. 10.1158/1078-0432.CCR-04-1773.CrossRefPubMed
27.
go back to reference Toji S, Yabuta N, Hosomi T, et al: The centrosomal protein Lats2 is a phosphorylation target of Aurora-A kinase. Genes Cells. 2004, 9: 383-97. 10.1111/j.1356-9597.2004.00732.x.CrossRefPubMed Toji S, Yabuta N, Hosomi T, et al: The centrosomal protein Lats2 is a phosphorylation target of Aurora-A kinase. Genes Cells. 2004, 9: 383-97. 10.1111/j.1356-9597.2004.00732.x.CrossRefPubMed
28.
go back to reference Jiang Z, Li X, Hu J, et al: Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res. 2006, 56: 450-8. 10.1016/j.neures.2006.09.006.CrossRefPubMed Jiang Z, Li X, Hu J, et al: Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res. 2006, 56: 450-8. 10.1016/j.neures.2006.09.006.CrossRefPubMed
29.
go back to reference Jimenez-Velasco A, Roman-Gomez J, Agirre X, et al: Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia. Leukemia. 2005, 19: 2347-50. 10.1038/sj.leu.2403974.CrossRefPubMed Jimenez-Velasco A, Roman-Gomez J, Agirre X, et al: Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia. Leukemia. 2005, 19: 2347-50. 10.1038/sj.leu.2403974.CrossRefPubMed
30.
go back to reference Zhao B, Lei QY, Guan KL: The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol. 2008, 20: 638-46. 10.1016/j.ceb.2008.10.001.CrossRefPubMedPubMedCentral Zhao B, Lei QY, Guan KL: The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol. 2008, 20: 638-46. 10.1016/j.ceb.2008.10.001.CrossRefPubMedPubMedCentral
31.
go back to reference Overholtzer M, Zhang J, Smolen GA, et al: Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA. 2006, 103: 12405-10. 10.1073/pnas.0605579103.CrossRefPubMedPubMedCentral Overholtzer M, Zhang J, Smolen GA, et al: Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA. 2006, 103: 12405-10. 10.1073/pnas.0605579103.CrossRefPubMedPubMedCentral
32.
go back to reference Oka T, Mazack V, Sudol M: Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). J Biol Chem. 2008, 283: 27534-46. 10.1074/jbc.M804380200.CrossRefPubMed Oka T, Mazack V, Sudol M: Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). J Biol Chem. 2008, 283: 27534-46. 10.1074/jbc.M804380200.CrossRefPubMed
Metadata
Title
LATS2 is De-methylated and Overexpressed in Nasopharyngeal Carcinoma and Predicts Poor Prognosis
Authors
Yan Zhang
Chun-Fang Hu
Jing Chen
Li-Xu Yan
Yi-Xin Zeng
Jian-Yong Shao
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-538

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine